Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801584 | 1.00 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL1627440 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4140372 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29541499 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4154180 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4148516 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4143916 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4149480 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL267542 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL19886817 | 0.87 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| CN-101501021-A | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2035407-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142584-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142584-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1015479-A4 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1015479-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5942387-A | Combinatorial process for preparing substituted thiophene libraries | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998046631-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997022342-A1 | NOVEL METHOD | NOVO NORDISK A/S (DK) | 1997-06-26 | — | — | WO | disclosed |
| CN-1142183-A | A method of treating neurogenic inflammation | NOVO NORDISK AS (DK) | 1997-02-05 | — | — | CN | disclosed |
| EP-0735872-A1 | A METHOD OF TREATING NEUROGENIC INFLAMMATION | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | disclosed |
| EP-0585314-B1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS | NOVO NORDISK AS (DK) | 1996-09-18 | — | — | EP | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| WO-1995018615-A1 | A METHOD OF TREATING NEUROGENIC INFLAMMATION | NOVO NORDISK A/S (DK) | 1995-07-13 | — | — | WO | disclosed |
| US-5348965-A | N-substituted azaheterocyclic carboxylic acids | NOVO NORDISK A/S (DK) | 1994-09-20 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0585314-A1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS. | NOVO NORDISK AS (DK) | 1994-03-09 | — | — | EP | disclosed |
| WO-1992020658-A1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS | NOVO NORDISK A/S (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | CHRM1, CHRM2, CHRM5 | USP2 3667/4885TSHR 176/4885KDM4E 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.